Recruiting

Testing a lung seal system for severe emphysema patients

Plain-English translation of NCT06035120 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated June 2026 · How we translate trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing the AeriSeal System, a treatment that seals small air channels in the lungs of people with severe emphysema. The goal is to prepare patients for a valve procedure (called BLVR with Zephyr Valve) that can help them breathe better. If this treatment works, it could help more patients benefit from the valve procedure.

Some emphysema patients have collateral ventilation—extra air pathways that bypass the damaged lung tissue. This can prevent valve procedures from working well. This medication aims to seal those pathways, so more patients can safely and effectively receive valve treatment.

Do you qualify?

You likely qualify if…

you are between 40 and 80 years old
you have severe emphysema with significant damage in at least one lung lobe, and your lungs show uneven damage (the target lobe is much more damaged than nearby lobes)
you have stopped smoking for at least 8 weeks before enrolling
you have completed a pulmonary rehabilitation program within the past 12 months
you have moderate to significant shortness of breath and can walk between 150 and 450 meters in 6 minutes
you have confirmed collateral ventilation (extra air pathways) in your target lung lobe

You likely don't qualify if…

you have had prior lung surgery, lung transplantation, or previous lung valve procedures (with some exceptions)
you have a lung nodule larger than 0.8 cm that has not been evaluated as benign
you have an active lung infection or significant other lung disease
you are currently unable or unwilling to follow medical treatment plans

What participation looks like

You will undergo a bronchoscopy procedure (a camera passed through your airways) to confirm collateral ventilation and then receive the AeriSeal treatment to seal those pathways. If the sealing does not fully work after 45 days, you may receive a second treatment. If successful, you will then receive the valve procedure as part of standard care. You will be followed for 24 months total to monitor your safety and how well the treatment works.

AI-generated summary from trial data · Jun 8, 2026 · Not medical advice

Trial locations(38 sites)

United States

Banner University Medical Center, Phoenix, Arizona

UCHealth - Medical Center of the Rockies, Loveland, Colorado

Saint Francis Hospital and Medical Center (Trinity Health of New England), Hartford, Connecticut

Orlando Health, Orlando, Florida

Northwestern University, Chicago, Illinois